title: Impact of whole-body MRI and FDG-PET on staging and assessment of therapy response in a patient with Ewing sarcoma.
abstract: In patients with Ewing sarcoma, precise staging is not only crucial for the therapeutic regimen but also for a reliable evaluation of response to therapy. We report on a 15-year-old girl with metastatic spread of a Ewing sarcoma who, apart from conventional staging by bone scan, chest X-ray and CT, was subsidiary examined by FDG-PET and whole-body MRI before and after chemotherapy. Both modalities detected more bone lesions than the bone scan, which led to an altered strategy for radiotherapy. Both examinations might be a great asset to stage-adjusted therapy regimens, ultimately influencing patient outcome.
authors.affiliation: Klinik für Strahlenheilkunde, Bereiche Diagnostische Radiologie und Nuklearmedizin, Charité-Universitätsmedizin, Berlin, Germany. christian.furth@charite.de
authors.forename: C
authors.initials: C
authors.lastname: Furth
authors.forename: H
authors.initials: H
authors.lastname: Amthauer
authors.forename: T
authors.initials: T
authors.lastname: Denecke
authors.forename: J
authors.initials: J
authors.lastname: Ruf
authors.forename: G
authors.initials: G
authors.lastname: Henze
authors.forename: M
authors.initials: M
authors.lastname: Gutberlet
mesh_terms: D000293:Adolescent; D001859:Bone Neoplasms / Q000175:diagnosis* / Q000556:secondary / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods*; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography / Q000379:methods*; D011237:Predictive Value of Tests; D012512:Sarcoma, Ewing / Q000175:diagnosis* / Q000556:secondary / Q000628:therapy*; D012680:Sensitivity and Specificity